Our friends at Thermosome continue to move their drug targeting platform forward. In a recent video, they describe the development of their drug targeting system using focal heat as the release trigger.
BSD-2000 3D/MR makes an appearance at 01:03
Thermosome has developed a drug release system that targets the tumor with a 10x to 15x higher local drug concentration over standard delivery. They do this by micro-encapsulating approved chemo drugs with a shell of thermosensitive liposomes (TSL). TSL holds tight to the chemotherapy drug, only releasing it when the surrounding environment reaches 42˚C, which is 5˚C higher than average body temperature.
Deep Regional Hyperthermia plays a role by creating the necessary 42˚C microenvironment around the tumor. Combining Thermosome with the BSD-2000 3D/MR provides stable temperatures in a defined focal region. The visual aspect of the MRI guidance (3D heat zone mapping) offers operator assurance that the tumor area is entirely at the target temperature when the drug is administered.
The TSL encapsulated drug is circulated via IV to the patient during the thermal therapy treatment. As the drug circulates throughout the body, TSL's release their payload inside the targeted area within the bloodstream. The portion of the TSL encapsulated drug that does not release in the tumor site flushes out of the body. Additional patient benefit is derived from the positive effects of increased blood flow and perfusion at the tumor site, the immune modulation generated by heating, and the increased concentration of chemotherapeutics.
Thermosome is actively looking for partners, learn more about at http://www.thermosome.com/